Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)

<strong>Background: </strong>Cardiovascular safety concerns for major cardiovascular events (MACE) were raised during the clinical trials of romosozumab. We aimed to evaluate the cardiovascular safety profile of romosozumab in a large pharmacovigilance database. <b>Methods:</b&g...

Full description

Bibliographic Details
Main Authors: Annika Vestergaard Kvist, Junaid Faruque, Enriqueta Vallejo-Yagüe, Stefan Weiler, Elizabeth M. Winter, Andrea M. Burden
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/10/8/1660

Similar Items